On February 28, 2023, Nichi-Iko Pharmaceutical Co., Ltd. sold all issued and outstanding shares of its wholly owned subsidiaries, Sagent Pharmaceuticals, based in Wyoming, and Omega Laboratories Ltd., based in Montreal, to Ellimist Singapore Pte. Ltd. for an aggregate purchase price of US$100 million.
Nichi-Iko Pharmaceutical Co.,Ltd. is a Japanese company that focuses on manufacturing and selling pharmaceutical and medical products.
Osler, Hoskin & Harcourt LLP advised Nichi-Iko Pharmaceutical Co. with a team led by Vincent de Grandpré (IP) and Hugo-Pierre Gagnon (Corporate) and consisting of Josh Blatt (Corporate), Alain Fournier and Jean-Philippe Dionne (Tax), Julien Ranger-Musiol and Jeremy Perron (Pension, Benefits & Employment), Shuli Rodal (Competition), Susan Newell (Health), Jennifer Fairfax (Environmental), Yan Besner and Natasha Vincelli (Real Estate), Alan Kenigsberg and Malcolm Aboud (Sanctions and Anti-Corruption) and Joanna Fine, Adam LaRoche and Gemma Devir (Privacy).
Key Contact
Partner, Corporate, Montréal
Team
Associate, Pensions and Benefits, Montréal
Manager, Student Programs, and Recruitment, Montréal
Associate, Corporate, Montréal
Partner, Tax, Toronto
Partner, Health, Toronto
Partner, Real Estate, Montréal
Associate, Privacy and Data Management; Employment and Labour, Calgary
Partner, Litigation; Regulatory, Indigenous and Environmental, Toronto
Partner, Pensions and Benefits, Montréal
Counsel, Disputes, Toronto
Associate, Tax, Montréal
Partner, Privacy and Data Management, Toronto
Partner, Tax, Montréal
Partner, Competition/Antitrust and Foreign Investment
Chair, Diversity Committee, Toronto
